1
|
Liang Y, Zhou X, Xie Q, Sun H, Huang K, Chen H, Wang W, Zhou B, Wei X, Zeng D, Lin H. CD146 interaction with integrin β1 activates LATS1-YAP signaling and induces radiation-resistance in breast cancer cells. Cancer Lett 2022; 546:215856. [PMID: 35944750 DOI: 10.1016/j.canlet.2022.215856] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2022] [Revised: 07/14/2022] [Accepted: 07/30/2022] [Indexed: 02/05/2023]
Abstract
Radiotherapy is an indispensable modality in comprehensive treatment of breast cancer. However, inherent or acquired radiation resistance of tumors compromises the efficacy of radiotherapy. Herein, we found that CD146, a unique epithelial-to-mesenchymal transition (EMT) inducer particularly highly expressed in triple-negative breast cancer (TNBC), is dramatically induced by ionizing irradiation. Further study demonstrates that CD146 promotes tumor cell radioresistance in vitro and in vivo. Specifically, we report the underlying mechanism that CD146 activates YAP protein, and drives its relocation from plasma to nucleus by regulating LATS1, and promoting abnormal DNA damage repair, as well as inducing EMT and stemness. Moreover, CD146 can form a novel co-receptor complex with integrin β1 and induces radiation-resistance in breast cancer. Dual inhibition of CD146 and integrin β1 activity had a stronger inhibitory effect on breast cancer tumor growth and synergistically increased their sensitivity to radiotherapy. This study identifies a unique function of CD146 implicates with integrin β1 and YAP signaling, contributing to radiation resistance. Targeted therapy against CD146 or inhibition of integrin β1 is a potential strategy to overcome radiotherapeutic resistance of breast cancer.
Collapse
Affiliation(s)
- Yuanke Liang
- Department of Thyroid and Breast Surgery, Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College (SUMC), 57 Changping Road, Shantou, 515000, China; Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Breast Cancer, Shantou, 515000, China
| | - Xiaoling Zhou
- Department of Prenatal Diagnosis, The First Affiliated Hospital of SUMC, Shantou, 515000, China
| | - Qin Xie
- Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Breast Cancer, Shantou, 515000, China; Department of Medical Oncology, Cancer Hospital of SUMC, Shantou, 515000, China
| | - Hexing Sun
- Department of Thyroid and Breast Surgery, Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College (SUMC), 57 Changping Road, Shantou, 515000, China
| | - Kaiyuan Huang
- Department of Thyroid and Breast Surgery, Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College (SUMC), 57 Changping Road, Shantou, 515000, China
| | - Huan Chen
- Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Breast Cancer, Shantou, 515000, China
| | - Wende Wang
- Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Breast Cancer, Shantou, 515000, China; Department of Medical Oncology, Cancer Hospital of SUMC, Shantou, 515000, China
| | - Benqing Zhou
- Department of Biomedical Engineering, College of Engineering, Shantou University, Shantou, 515000, China
| | - Xiaolong Wei
- Department of Pathology, Cancer Hospital of SUMC, 515000, China
| | - De Zeng
- Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Breast Cancer, Shantou, 515000, China
- Department of Medical Oncology, Cancer Hospital of SUMC, Shantou, 515000, China
| | - Haoyu Lin
- Department of Thyroid and Breast Surgery, Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College (SUMC), 57 Changping Road, Shantou, 515000, China
- Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Breast Cancer, Shantou, 515000, China
| |
Collapse
|